NCT04964947View on ClinicalTrials.gov

Tobramycin Injection to Prevent Infection in Open Fractures

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

600

Participants

Timeline

Start Date

January 10, 2022

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2026

Conditions
Wound InfectionFractures, OpenSurgical Site Infection
Interventions
DRUG

Tobramycin Injection

80 milligrams of tobramycin diluted in 40 milliliters of normal saline

Trial Locations (3)

37232

Vanderbilt University Medical Center, Nashville

40536

University of Kentucky, Lexington

02114

Massachusetts General Hospital, Boston

All Listed Sponsors
collaborator

United States Department of Defense

FED

lead

Massachusetts General Hospital

OTHER